ISB News

Melding ISB and FHCRC Brain Power for Cancer Research

ISB's Ilya Shmulevich describes his lab's work in The Cancer Genome Atlas project and how ISB and FHCRC could collaborate.

(Photo above: ISB’s Dr. Ilya Shmulevich describes his lab’s work in The Cancer Genome Atlas project and how ISB and FHCRC could collaborate.)

Big health challenges require big science. Cancers are prime examples of overwhelmingly complex diseases that need the power of a cross-disciplinary, systems biology approach to decipher the underlying dysfunctional gene networks in order to find ways to prevent and manage the diseases and develop more effective therapies.

ISB's Dr. Nathan Price, left, chats with FHCRC's Dr. David Hockenbery and Dr. Eric Holland during a meeting held at Institute for Systems Biology to discuss potential collaborations on cancer research.

ISB’s Dr. Nathan Price, left, chats with FHCRC’s Dr. David Hockenbery and Dr. Eric Holland during a meeting held at Institute for Systems Biology to discuss potential collaborations on cancer research.

On May 6 at Institute for Systems Biology, researchers from ISB and Fred Hutchinson Cancer Research Center – specifically the Human Biology Division – gathered for a meeting of great minds to identify potential areas for collaboration. It was an intimate showcase for commingling ISB’s pioneering systems approach with the depth of cancer biology knowledge from FHCRC.

 

“We are laying the foundation for a strategic partnership that combines the best of both institutions to attack cancers with systems biology.”

Dr. Nitin Baliga, Senior Vice President and Director of ISB, and project coordinator Dr. Julie Bletz, worked with Dr. Eric Holland, Senior Vice President and Director of the Human Biology Division at FHCRC, to organize the day-long meeting. After introductions, 15 ISB and FHCRC researchers alternated to present their areas of expertise, research challenges, what strengths his/her group could bring to the table and what complementary collaboration the group seeks. The 15 rapid-fire presentations consisted of 15-minute research summaries plus 5 minutes for questions and answers.

The day concluded with group discussions on three topics: potential partnerships and funding opportunities that can be pursued at the investigator level; types of resources both institutions can share and invest in jointly; one or two big problems that both organizations can attack collectively.

“It was a great day, with lots of interesting discussions and potential for collaboration,” said Baliga. “We are laying the foundation for a strategic partnership that combines the best of both institutions to attack cancers with systems biology.”

Recent Articles

  • Timing is Everything: ISB Study Finds Link Between Bowel Movement Frequency and Overall Health

    Everybody poops, but not every day. An ISB-led research team examined the clinical, lifestyle, and multi-omic data of more than 1,400 healthy adults. How often people poop, they found, can have a large influence on one’s physiology and health.

  • Wei Wei, PhD

    Dr. Wei Wei Promoted to Associate Professor

    Wei Wei, PhD – an accomplished cancer researcher with expertise in biotechnology and cancer systems biology – has been promoted to ISB associate professor. The Wei Lab focuses on understanding how cancer cells adapt to therapeutic treatment to foster therapy resistance by coordinating their internal molecular machinery and how these adaptive changes evolve within diverse tumors influenced by the tumor microenvironment. 

  • Drs. Nitin Baliga and James Park

    How Glioblastoma Resists Treatment – and Ways to Prevent It

    Glioblastoma is one of the deadliest and most aggressive forms of primary brain cancer in adults and is known for its ability to resist treatment and to recur. ISB researchers have made breakthrough discoveries in understanding the mechanisms behind acquired resistance, focusing on a rare and stubborn group of cells within tumors called glioma stem-like cells.